Form 4: C4 Therapeutics Director Acquires Stock Options

C4 Therapeutics, Inc. reports that Director Ronald Harold Wilfred Cooper acquired 62,000 stock options with an exercise price of $4.25.

Summary

• Ronald Harold Wilfred Cooper, a Director at C4 Therapeutics, Inc., acquired 62,000 stock options on June 24, 2026.
• The stock options have an exercise price of $4.25 per share.
• These options are set to expire on June 23, 2036.
• The options will vest and become exercisable in full on the earlier of June 24, 2027, or the next annual stockholder meeting, provided Cooper remains on the Board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director rather than a significant financial event or strategic shift.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of 62,000 options represents a significant grant to a key executive.

Risks

• The value of the stock options is contingent on the future performance of C4 Therapeutics' stock price.
• Vesting conditions tied to continued service and specific dates introduce potential forfeiture if circumstances change.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the fulfillment of vesting conditions.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive interests with shareholder value and incentivize long-term performance.

Stakeholder Impact

• Shareholders: The issuance of options could lead to future dilution if exercised, but also signals management's commitment to increasing shareholder value.
• Employees: May be indirectly impacted by the company's performance, which the options are tied to.
• Management: Directly incentivized to improve company performance and stock price.

Next Steps

• The stock options will vest and become exercisable based on the specified conditions.
• The reporting person may exercise these options in the future, subject to market conditions and company performance.

Key Dates

Keywords

C4 Therapeutics, CCCC, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Award